![Graham Walmsley](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Graham Walmsley
Direktor/Vorstandsmitglied bei
OLEMA PHARMACEUTICALS, INC.
Vermögen: - $ am 30.06.2026
Profil
Graham Gordon Walmsley is the founder of Logos Capital Fund LLP, founded in 2019, serving as Managing Partner.
Dr. Walmsley is the founder of Logos Global Management LP, founded in 2019, serving as General Partner.
Current jobs include Managing Partner at Logos Capital LLC, Independent Director at Olema Pharmaceuticals, Inc. since 2020, and Director at ALX Oncology, Inc. since 2020.
Former jobs include Independent Director at Lifesci Acquisition II Corp., Independent Director at ALX Oncology Holdings, Inc. from 2020 to 2021, Director at Science 37 Holdings, Inc., Independent Director at Akero Therapeutics, Inc. from 2018 to 2025, Principal at Versant Venture Management LLC from 2016 to 2019, Head-Business Development at Jecure Therapeutics, Inc. from 2017 to 2018, and Head-Business Development at Contineum Therapeutics, Inc. in 2018.
Education includes an undergraduate degree from the University of California, Berkeley in 2009 and a doctorate from Stanford University School of Medicine in 2016.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Graham Walmsley
| Unternehmen | Position | Beginn |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.03.2020 |
Logos Capital Fund LLP
 Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund | Gründer | 01.08.2019 |
ALX Oncology, Inc.
 ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers | Direktor/Vorstandsmitglied | 01.02.2020 |
Logos Global Management LP
 Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries. | Gründer | 01.03.2019 |
Ehemalige bekannte Positionen von Graham Walmsley
| Unternehmen | Position | Ende |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 09.12.2025 |
| ALX ONCOLOGY HOLDINGS INC. | Direktor/Vorstandsmitglied | 01.08.2021 |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Private Equity Investor | 01.08.2019 |
| CONTINEUM THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2018 |
Jecure Therapeutics, Inc.
 Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis | Corporate Officer/Principal | 01.11.2018 |
Ausbildung von Graham Walmsley
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
81
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Logos Capital Fund LLP
Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Functions as a pooled investment fund | Miscellaneous |
Jecure Therapeutics, Inc.
Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis | Commercial Services |
Akero Therapeutics, Inc.
 Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
ALX Oncology, Inc.
ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company which develops therapies for cancers | Health Technology |
Logos Global Management LP
Logos Global Management LP Investment ManagersFinance Logos seeks to generate superior risk adjusted returns. The firm intends to deliver capital appreciation for the Public Funds primarily through a mix of long and short investment strategies, including a number of hedging strategies to preserve capital and manage risk exposure. Most of the Public Funds’ assets are expected to be invested on a global basis in publicly traded equity securities in the healthcare and life sciences industries. | Finance |
Pipeline Therapeutics, Inc.
 Pipeline Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel, oral small molecule therapies for neuroscience, inflammation and immunology indications | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
Lifesci Acquisition II Corp.
 Lifesci Acquisition II Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Science 37 Holdings, Inc.
 Science 37 Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research company | Commercial Services |
